Source comparison
MOTS-c Mitochondrial Function: Administration Variables Comparison
Dosing Frequency 5mg 3×/week subcutaneous 10mg 3×/week or 5mg daily 5mg 1–2×/week or inconsistent timing Dosing consistency drives AMPK signaling stability. Irregular schedules reset the adaptation curve and delay Phase 2 entry by 2–3 weeks Storage Integrity R
This comparison does not assign a generated winner or score.
- Dosing Frequency
- 5mg 3×/week subcutaneous
- 10mg 3×/week or 5mg daily
- 5mg 1–2×/week or inconsistent timing
- Dosing consistency drives AMPK signaling stability. Irregular schedules reset the adaptation curve and delay Phase 2 entry by 2–3 weeks
- Storage Integrity
- Refrigerated 2–8°C, used within 28 days post-reconstitution
- Temperature-monitored cold storage, immediate use post-thaw
- Ambient storage, multiple freeze-thaw cycles, >28 days old
- Temperature excursions denature peptide structure irreversibly. This is the #1 cause of 'non-response' complaints
- Training Stimulus
- 3–4 resistance or endurance sessions/week
- 5–6 structured sessions with progressive overload
- Sedentary or irregular activity
- Mitochondrial biogenesis requires training stimulus. MOTS-c signals need, exercise provides demand
- Caloric Intake
- Maintenance or +200–300 surplus
- Maintenance with high protein (1.6–2.2g/kg)
- Severe deficit (<1200 kcal) or erratic intake
- Energy restriction during Phase 2 blunts mitochondrial biogenesis. The peptide works, but the body lacks resources to build new organelles
- Baseline Metabolic Health
- HOMA-IR 1.5–3.0, fasting glucose 90–110 mg/dL
- HOMA-IR <1.5, fasting glucose <90 mg/dL
- HOMA-IR >4.0, HbA1c >6.5%
- Severe insulin resistance or diabetes reduces GLUT4 responsiveness. Outcomes are measurable but smaller in magnitude